Lunit Advances to Stage 2 of Australia's National Breast Cancer Screening Project
After a successful stage 1, Lunit INSIGHT MMG moves to prospective validation in Australia's BreastScreen NSW Machine Reading Solution Project SEOUL, South Korea, Dec. 11, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced its progression to the second stage of the BreastScreen NSW (BSNSW) Machine Reading Solution Project....
Source: asiaone.com